Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glanzmann thrombasthenia.

Alan T Nurden1

  • 1IFR No4/CRPP, Laboratoire d'Hématologie, Hôpital Cardiologique, 33604 Pessac, France. Alan.Nurden@cnrshl.u-bordeaux2.fr

Orphanet Journal of Rare Diseases
|May 26, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reduced platelet formation associated with serine metabolic dysregulation in integrin αIIbβ3-deficient megakaryocytes.

Blood·2026
Same author

Platelet-derived integrin- and tetraspanin-enriched tethers exacerbate severe inflammation.

Science (New York, N.Y.)·2026
Same author

Glanzmann Thrombasthenia 10 Years Later: Progress Made and Future Directions.

Seminars in thrombosis and hemostasis·2024
Same author

The GPIIb-IIIa defect of platelets in Glanzmann thrombasthenia.

Haematologica·2023
Same author

A single F153Sβ3 mutation causes constitutive integrin αIIbβ3 activation in a variant form of Glanzmann thrombasthenia.

Blood advances·2023
Same author

Molecular basis of clot retraction and its role in wound healing.

Thrombosis research·2022

Glanzmann thrombasthenia is a rare bleeding disorder caused by defects in platelet aggregation due to alphaIIb beta3 integrin issues. Early diagnosis and careful management, including desmopressin and platelet transfusions, lead to an excellent prognosis.

Area of Science:

  • Hematology
  • Genetics
  • Molecular Biology

Background:

  • Glanzmann thrombasthenia (GT) is a rare autosomal recessive bleeding disorder.
  • It affects platelet aggregation due to abnormalities in the alphaIIb beta3 integrin.
  • This integrin is crucial for platelet adhesion and thrombus formation.

Purpose of the Study:

  • To summarize the clinical presentation, diagnosis, and management of Glanzmann thrombasthenia.
  • To highlight the molecular basis and variability of the disease.
  • To emphasize the importance of early diagnosis and appropriate treatment for a favorable prognosis.

Main Methods:

  • Review of clinical and molecular findings in Glanzmann thrombasthenia.
  • Discussion of diagnostic criteria, including platelet aggregation tests and flow cytometry.

Related Experiment Videos

  • Outline of therapeutic strategies, including local hemostasis, desmopressin, platelet transfusions, and recombinant factor VIIa.

    • Main Results:

    • GT presents with variable mucocutaneous bleeding, with purpura, epistaxis, and menorrhagia being common.
    • Diagnosis relies on absent platelet aggregation despite normal platelet counts and morphology, confirmed by alphaIIb beta3 integrin assessment.
    • Effective management strategies significantly improve patient outcomes.

    Conclusions:

    • Glanzmann thrombasthenia, while potentially severe, has an excellent prognosis with proper supportive care.
    • Avoiding platelet alloimmunization is key in therapeutic management.
    • Timely and accurate diagnosis is essential for effective treatment and improved quality of life.